Kidney Cancer

Low, But Increasing, Use of Palliative Care Seen in RCC

By

Andrea S. Blevins Primeau, PhD, MBA

Publish Date November 16, 2020

Patients who were Black, had higher incomes, or who had undergone surgery were less likely to receive palliative care.

Modified Nivolumab-Ipilimumab Dosing Shows No Benefit in Advanced RCC

By

Andrea S. Blevins Primeau, PhD, MBA

Publish Date November 12, 2020

A modified dosing regimen of nivolumab-ipilimumab for patients with advanced RCC did not provide additional benefit compared with standard dosing.

Phase 3 Study to Evaluate HIF-2α Inhibitor in RCC

By

Andrea S. Blevins Primeau, PhD, MBA

Publish Date November 10, 2020

A phase 3, randomized, active-controlled trial will evaluate the efficacy and safety of a HIF-2α inhibitor for the second-line treatment of clear cell RCC.

Phase 2 Study Initiated for HIF-2α Agent in Relapsed/Refractory RCC

By

Andrea S. Blevins Primeau, PhD, MBA

Publish Date November 10, 2020

A phase 2 trial has been initiated to evaluate a HIF-2α inhibitor for the treatment of advanced RCC after progression with another therapy.

Patient-Specific Characteristics and Costs Related to Oral Targeted Therapy in Metastatic RCC

By

Susan Moench, PhD, PA-C

Publish Date October 30, 2020

Age, marital status, and geographic location tended to influence use of oral anticancer therapy in older patients with metastatic RCC.